The pharmacotherapy of alcohol dependence: a state of the art review (Q34543952)

2 August 2017

The pharmacotherapy of alcohol dependence: a state of the art review (English)

1 reference

2 August 2017

0 references

1 reference

Avinash De Sousa

1

1 reference

PubMed ID

21327171

2 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

2 August 2017

1 reference

2 August 2017

8

1 reference

2 August 2017

1

1 reference

2 August 2017

69-82

1 reference

Pharmacoprophylaxis of alcohol dependence: Review and update Part I: Pharmacology

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The state of pharmacotherapy for the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone for the management of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Combining psychosocial treatment with pharmacotherapy for alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The status of disulfiram: a half of a century later

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Rationale for combining acamprosate and naltrexone for treating alcohol dependence.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Acamprosate in the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Pharmacotherapy of alcohol dependence: a review of the clinical data

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Current pharmacotherapies of alcoholism: a U.S. perspective.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

NMDA receptors in alcoholism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Does disulfiram have a role in alcoholism treatment today?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Treatment of alcohol-dependent outpatients with acamprosate: a clinical review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Topiramate blocks kainate-evoked cobalt influx into cultured neurons

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Drug therapy for alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Pharmacological treatment of alcohol dependence: a review of the evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The efficacy of disulfiram: a review of outcome studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Endogenous opioid systems and alcohol addiction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A risk-benefit assessment of naltrexone in the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Dosing issues in the pharmacotherapy of alcoholism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone increases the latency to drink alcohol in social drinkers.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Low plasma homovanillic acid levels in recently abstinent alcoholic men.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Effect of haloperidol on measures of craving and impaired control in alcoholic subjects.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Endogenous opioids and excessive alcohol consumption

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The clinical use of disulfiram (Antabuse): a review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Piecing together the puzzle of basal forebrain anatomy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Disulfiram therapy--adverse drug reactions and interactions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Depot preparations of disulfiram: experimental and clinical results

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone in the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Alteration of ethanol effects by opiate antagonists

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Temporal variation in deaths related to alcohol intoxication and drinking

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone's effect on cue-elicited craving among alcoholics in treatment.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Naltrexone-induced alterations in human ethanol intoxication.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031941

Disulfiram treatment of alcoholism

27 October 2018

1 reference

12 December 2020

Preventing disulfiram hepatitis in alcohol abusers: inappropriate guidelines and the significance of nickel allergy

1 reference

12 December 2020

An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence

1 reference

12 December 2020

Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome

1 reference

12 December 2020

Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats

1 reference

12 December 2020

Long-term, high-dose disulfiram in the treatment of alcohol abuse

1 reference

12 December 2020

Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol

1 reference

12 December 2020

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study

1 reference

12 December 2020

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence

1 reference

12 December 2020

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

12 December 2020

Disulfiram in context: structure and safety

1 reference

12 December 2020

Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study

1 reference

12 December 2020

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial

1 reference

12 December 2020

Evidence-based treatments for alcohol dependence: new results and new questions

1 reference

12 December 2020

Study of hepatotoxicity of naltrexone in the treatment of alcoholism

1 reference

12 December 2020

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study

1 reference

12 December 2020

Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder

1 reference

12 December 2020

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

1 reference

12 December 2020

Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive-Behavioral Therapy in Type B Alcoholics

1 reference

12 December 2020

Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism

1 reference

12 December 2020

Disulfiram-ethanol test reaction: significance of supervision

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.4103/0973-1229.58820

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

21327171